Fairmount Funds Management as of March 31, 2025
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 15 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 14.7 | $95M | 815k | 116.63 | |
| Apogee Therapeutics (APGE) | 11.9 | $77M | 2.0M | 37.36 | |
| Spyre Therapeutics Com New (SYRE) | 10.1 | $65M | 4.0M | 16.14 | |
| Enliven Therapeutics (ELVN) | 9.8 | $63M | 3.2M | 19.68 | |
| Nuvalent Inc-a (NUVL) | 8.0 | $52M | 728k | 70.92 | |
| Dianthus Therapeutics (DNTH) | 7.6 | $49M | 2.7M | 18.14 | |
| Miragen Therapeutics (VRDN) | 7.2 | $46M | 3.4M | 13.48 | |
| Scholar Rock Hldg Corp (SRRK) | 6.9 | $44M | 1.4M | 32.15 | |
| Cogent Biosciences (COGT) | 5.8 | $37M | 6.2M | 5.99 | |
| Oruka Therapeutics (ORKA) | 5.4 | $35M | 3.4M | 10.26 | |
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 3.8 | $25M | 1.1M | 22.21 | |
| Astria Therapeutics (ATXS) | 2.9 | $19M | 3.6M | 5.34 | |
| Zenas Biopharma (ZBIO) | 2.3 | $15M | 1.9M | 7.90 | |
| Inhibikase Therapeutics Com New (IKT) | 2.1 | $13M | 6.1M | 2.19 | |
| Bicara Therapeutics (BCAX) | 1.6 | $10M | 784k | 13.03 |
